Breaking News

ABL Bio, GenScript Enter Bispecific Antibody Alliance

GenScript will serve as ABL Bio’s exclusive supplier of CDMO services for IND-enabling studies and clinical material manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GenScript Biologics, a biopharmaceutical CDMO, has entered into an agreement with ABL Bio Inc., a South Korean biotech company dedicated to therapeutics for immuno-oncology and neurodegenerative diseases, for two bispecific antibody programs. GenScript will grant a sublicense to ABL Bio to use sdAb (single-domain antibody), mAb (monoclonal antibody) targeting tumor antigens, and its Single-Domain Antibody fused to Monoclonal Ab (SMAB) Platform to develop several bispecific antibody molecules....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters